Asep Medical Holdings Inc (SEPSF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAsep Medical Holdings Inc (SEPSF) trades at $0.0109. Asep Medical Holdings Inc. is a biotechnology company focused on developing an early diagnostic tool for sepsis and peptide therapeutic treatments. Sector: Healthcare.
Price as of Sep 10, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SEPSF: SEPSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SEPSF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
SEPSF: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Asep Medical Holdings Inc (SEPSF) Healthcare & Pipeline Overview
Asep Medical Holdings Inc., a biotechnology firm, is dedicated to pioneering an early sepsis diagnostic tool and peptide therapeutics. Operating through ASEP Medical Inc., the company targets critical unmet needs in healthcare, though it faces challenges common to early-stage biotech ventures in a competitive landscape.
What Is the Investment Thesis for SEPSF?
Asep Medical Holdings Inc. presents a high-risk, high-reward investment opportunity. The company's focus on early sepsis diagnosis addresses a critical medical need, potentially capturing a significant market share if successful. However, the company's negative P/E ratio of -2.42 and a substantial negative profit margin of -38918.3% indicate significant financial challenges. The development of peptide therapeutics offers additional upside, but the timeline for clinical trials and regulatory approvals is uncertain. Investors should carefully consider the company's limited operating history, small employee base, and the inherent risks associated with biotechnology investments. The beta of -1.55 suggests the stock moves inversely to the market, but this may not hold true long term given the company's stage.
Based on FMP financials and quantitative analysis
SEPSF Key Highlights
Asep Medical Holdings Inc. is focused on developing an early diagnostic tool for sepsis, addressing a critical unmet medical need.
- The company's research also extends to peptide therapeutic treatments for multiple applications, diversifying its potential revenue streams.
- Asep Medical Holdings Inc. was incorporated in 2020, making it a relatively young company in the biotechnology sector.
- The company's negative P/E ratio of -2.42 and profit margin of -38918.3% reflect its current stage of development and investment in research and development.
- Asep Medical operates with a small team of six employees, indicating a lean operational structure.
Who Are SEPSF's Competitors?
SEPSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ELVAY Evolva Holding S.A. | $1.16 | 0.00% | — | |
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.84% | $194M | 785-pillar |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | 665-pillar |
| QTTB Q32 Bio Inc. | $10.77 | -3.37% | $320M | 685-pillar |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | 689-signal |
| CRMD CorMedix Inc. | $7.93 | -2.40% | $623M | 885-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are SEPSF's Key Strengths?
Focus on a critical unmet medical need (sepsis diagnosis).
- Proprietary technology in peptide therapeutics.
- Potential for first-mover advantage in the early sepsis diagnostics market.
- Lean operational structure with a small team.
What Are SEPSF's Weaknesses?
Early-stage company with limited operating history.
- Negative profitability and significant financial challenges.
- Reliance on successful development and commercialization of its products.
- Small employee base may limit its capacity to execute multiple projects simultaneously.
What Could Drive SEPSF Stock Higher?
Announcement of preclinical or clinical trial results for its sepsis diagnostic tool.
- Potential regulatory approvals for its diagnostic tool from health authorities.
- Progress in the development of its peptide therapeutic pipeline.
- Strategic partnerships or collaborations with pharmaceutical companies or research institutions.
- Securing government grants or funding for its research and development projects.
What Are the Key Risks for SEPSF?
Financial-distress signal — its Altman Z-Score of -5.80 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures or unexpected side effects of its products.
- Competition from established pharmaceutical and biotech companies.
- Regulatory hurdles and lengthy approval processes.
- Difficulty securing funding and maintaining financial stability.
- Limited operating history and small employee base.
What Are the Growth Opportunities for SEPSF?
- Asep Medical's success hinges on the successful development and commercialization of its early diagnostic tool. Positive clinical trial results and regulatory approvals could lead to significant revenue growth within the next 3-5 years.
- Expansion of Peptide Therapeutic Pipeline: Peptide therapeutics represent a growing area of pharmaceutical research, with applications in various diseases, including cancer, diabetes, and infectious diseases. Asep Medical's focus on peptide therapeutics offers the potential to expand its product pipeline and address multiple market segments. Successful preclinical and clinical studies could lead to partnerships with larger pharmaceutical companies and generate substantial revenue streams over the next 5-7 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with established pharmaceutical companies, research institutions, and healthcare providers can accelerate Asep Medical's research and development efforts, provide access to funding and expertise, and facilitate the commercialization of its products. Such collaborations could lead to milestone payments, royalties, and co-development agreements, enhancing the company's financial position and market reach within the next 2-3 years.
- Government Grants and Funding Opportunities: The biotechnology industry benefits from various government grants, funding programs, and tax incentives designed to support research and development. Asep Medical can leverage these opportunities to secure non-dilutive funding for its projects, reducing its reliance on equity financing and preserving shareholder value. Successful grant applications could provide significant financial resources over the next 1-2 years.
- Geographic Expansion into New Markets: Expanding into new geographic markets, such as Europe and Asia, can broaden Asep Medical's customer base and increase its revenue potential. This requires adapting its products and marketing strategies to meet the specific needs of each market. Successful market entry could lead to increased sales and brand recognition within the next 3-5 years.
What Are SEPSF's Competitive Advantages?
- Proprietary technology in sepsis diagnostics and peptide therapeutics.
- Patents protecting its diagnostic tool and therapeutic treatments.
- Expertise in peptide chemistry and drug development.
- First-mover advantage in the early sepsis diagnostics market.
What Does SEPSF Do?
Asep Medical Holdings Inc., established in 2020 and based in Vancouver, Canada, is a biotechnology company operating through its subsidiary, ASEP Medical Inc. The company is focused on developing an early diagnostic tool for sepsis, a life-threatening condition resulting from the body's overwhelming response to an infection. Early diagnosis is critical for effective treatment and improved patient outcomes. In addition to diagnostics, Asep Medical is also engaged in developing peptide therapeutic treatments for various applications. These treatments leverage the potential of peptides, which are short chains of amino acids, to modulate biological processes and address specific medical needs. The company, formerly known as Trenchant Life Sciences Investment Corp., transitioned to Asep Medical Holdings Inc. to reflect its focus on medical innovations. As a relatively young company with a small team of six employees, Asep Medical is in the early stages of its development, concentrating on research, development, and preclinical studies. The company's success hinges on the successful development and commercialization of its diagnostic tool and therapeutic treatments. Given its early stage, Asep Medical faces the typical challenges of biotechnology startups, including securing funding, navigating regulatory pathways, and demonstrating clinical efficacy.
What Products and Services Does SEPSF Offer?
- Develop an early diagnostic tool for sepsis, a life-threatening condition.
- Research and develop peptide therapeutic treatments for various applications.
- Focus on improving patient outcomes through early and accurate diagnosis of sepsis.
- Leverage peptide technology to modulate biological processes for therapeutic purposes.
- Conduct preclinical and clinical studies to evaluate the safety and efficacy of its products.
- Seek regulatory approvals from health authorities for its diagnostic tool and therapeutic treatments.
- Explore strategic partnerships and collaborations to accelerate research and development.
How Does SEPSF Make Money?
- Develop and patent novel diagnostic and therapeutic technologies.
- Conduct research and development to validate the efficacy of their products.
- Seek regulatory approval for their products to enable commercialization.
- Generate revenue through sales of diagnostic tools and therapeutic treatments, or through licensing agreements.
What Industry Does SEPSF Operate In?
Asep Medical Holdings Inc. operates within the biotechnology industry, a sector characterized by rapid innovation, high risk, and significant potential for reward. The development of new diagnostic tools and therapeutic treatments is driven by advancements in genomics, proteomics, and other areas of biomedical research. The sepsis diagnostics market is growing due to the increasing incidence of sepsis and the need for rapid and accurate diagnosis. Companies like CNBI and ELVAY are also active in the biotechnology space, developing various diagnostic and therapeutic solutions. The competitive landscape is intense, with both established pharmaceutical companies and emerging biotech firms vying for market share.
Who Are SEPSF's Key Customers?
- Hospitals and healthcare providers who need rapid and accurate sepsis diagnosis.
- Clinical laboratories that perform diagnostic testing.
- Pharmaceutical companies seeking novel therapeutic treatments.
- Research institutions involved in biomedical research.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 63 |
| 2026-08-26 | 63 |
| 2026-08-29 | 63 |
| 2026-09-01 | 63 |
| 2026-09-04 | 63 |
| 2026-09-07 | 63 |
| 2026-09-10 | 63 |
What changed?
The score has stayed at 63.
Over the same 18 days the stock moved +0.0%.
Key Financial Metrics
Return on assets is -48.2%, showing how much profit it generates from its asset base. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching.
SEPSF Revenue & Earnings Trend
In Q2 FY2026, SEPSF generated $72K in top-line revenue, marking a sequential decrease of 2.4%. The company recorded a net loss of $605K, with diluted EPS of $-0.04. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely. Across the four most recent quarters, SEPSF averaged $-0.09 in diluted EPS.
Company Profile
Asep Medical Holdings Inc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Victoria, CA. The company is led by CEO Richard Heinzl. SEPSF has traded publicly since 2022.
Financial Health
Asep Medical Holdings Inc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.80 places it in the distress zone, a signal of elevated financial risk.
SEPSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on a critical unmet medical need (sepsis diagnosis).
- Proprietary technology in peptide therapeutics.
- Potential for first-mover advantage in the early sepsis diagnostics market.
- Lean operational structure with a small team.
Bear Case
- Early-stage company with limited operating history.
- Negative profitability and significant financial challenges.
- Reliance on successful development and commercialization of its products.
- Small employee base may limit its capacity to execute multiple projects simultaneously.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | C$71,630 | -C$605,150 | -C$0.04 |
| Q1 FY2026 | C$73,365 | -C$274,016 | -C$0.02 |
| Q4 FY2025 | C$114,708 | -C$3M | -C$0.25 |
| Q3 FY2025 | C$74,803 | -C$486,405 | -C$0.04 |
Q2 FY2026 · filed 30 Jun 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis · Reported in CAD
SEPSF Latest News
No recent news available for SEPSF.
SEPSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SEPSF.
Price Targets
Wall Street price target analysis for SEPSF.
SEPSF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SEPSF; grades run from A+ (80-100) to F (below 30).
Leadership: Richard Heinzl
CEO
Richard Heinzl serves as the CEO of Asep Medical Holdings Inc., leading a team of six employees. His background includes experience in managing and growing early-stage companies, with a focus on strategic planning and execution. He is responsible for overseeing the company's research and development efforts, securing funding, and building relationships with key stakeholders. His expertise is crucial for guiding Asep Medical through the challenges of the biotechnology industry.
Track Record: Under Richard Heinzl's leadership, Asep Medical Holdings Inc. has focused on developing its early sepsis diagnostic tool and peptide therapeutic treatments. He has overseen the company's research and development efforts and worked to secure funding for its projects. His strategic decisions have been instrumental in shaping the company's direction and positioning it for future growth. However, given the company's early stage, it is difficult to assess long-term performance.
SEPSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Asep Medical Holdings Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This lack of stringent requirements often translates to higher risks for investors compared to exchange-listed companies.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry and makes it difficult to assess the company's true financial health.
- Lower regulatory oversight increases the risk of fraud and mismanagement.
- Limited liquidity can make it difficult to exit positions quickly and at favorable prices.
- Higher price volatility can lead to significant losses.
- The company may not meet the minimum listing requirements of major exchanges, limiting its access to capital and investor base.
- Verify the company's financial statements and SEC filings (if any) through independent sources.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Understand the company's capital structure and funding needs.
- Monitor the company's news releases and investor relations materials.
- Consult with a financial advisor before investing.
- The company is incorporated and has a registered business address.
- The company has a website and publishes investor relations materials.
- The company has a management team with relevant experience.
- The company is developing products that address a real market need.
- The company has secured patents or other intellectual property protection.
Asep Medical Holdings Inc Healthcare Stock: Key Questions Answered
Is SEPSF a good stock?
Stock Expert AI does not rate SEPSF buy, sell or hold. Asep Medical Holdings Inc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about SEPSF stock?
As of March 16, 2026, there is no readily available analyst coverage for SEPSF stock due to its OTC listing and early stage of development. Key valuation metrics such as revenue projections and earnings estimates are not widely available.
What are the key factors to evaluate for SEPSF?
Evaluate SEPSF on fundamentals, analyst consensus, and risk factors. The beta of -1.55 suggests the stock moves inversely to the market, but this may not hold true long term given the company's stage. Not financial advice.
How frequently does SEPSF data refresh on this page?
SEPSF's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SEPSF's recent stock price performance?
Asep Medical Holdings Inc (SEPSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a critical unmet medical need (sepsis diagnosis). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SEPSF overvalued or undervalued right now?
Asep Medical Holdings Inc (SEPSF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of SEPSF?
Yes, most major brokerages offer fractional shares of Asep Medical Holdings Inc (SEPSF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SEPSF's earnings and financial reports?
Asep Medical Holdings Inc (SEPSF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SEPSF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company is an early-stage biotechnology company, and its future performance is uncertain.